Novel Acetylcholinesterase Inhibitors Identified from ZINC Database Using Docking-Based Virtual Screening for Alzheimer's Disease.

被引:5
作者
Abdusalam, Ashraf Ahmed Ali [1 ]
Vikneswaran, Murugaiyah [2 ]
机构
[1] Sirte Univ, Fac Hlth Sci, Dept Pharmaceut Sci, Sirte, Libya
[2] Univ Sains Malaysia, Sch Pharmaceut Sci, Dept Pharmacol, George Town 11800, Malaysia
来源
CHEMISTRYSELECT | 2020年 / 5卷 / 12期
关键词
Acetylcholinesterase; Alzheimer's disease; Molecular docking; Virtual screening; ZINC database; DRUG; SYSTEM;
D O I
10.1002/slct.201904177
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disease related to ageing. Cholinesterases are a family of enzymes that catalyse the hydrolysis of acetylcholine (ACh), which is an essential process in the cholinergic neurotransmission. Cholinesterases can be divided into two types, namely acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). This paper reports virtual screening and molecular docking of 200 compounds obtained from the ZINC database, using AutoDock Vina and AutoDock 4.2 to find potential AChE inhibitors. Only compounds that are compliant with Lipinski's rule of five for drug-likeness properties were virtually screened to identify novel compounds that show similar or better interaction with the target protein compared to the coordinated ligand galantamine. The results showed that 6 compounds, namely ZINC10140364, ZINC08061148, ZINC34735322, ZINC05151975, ZINC33126088 and ZINC15805418, exhibited better free energy of binding (FEB) than galantamine, with AutoDock Vina scores of -9.88, -10.44, -10.30, -9.63, -8.35 and -9.42 kcal/mol and AutoDock scores of -12.3, -11.6, -11.0, -10.9, -10.5 and -9.3 kcal/mol, respectively. In conclusion, the results obtained suggest that the 6 compounds are potential AChE inhibitors suitable for further evaluation and development as potential agents for treatment.
引用
收藏
页码:3593 / 3599
页数:7
相关论文
共 27 条
  • [1] Atkinson F., 2002, Current Medicinal Chemistry - Central Nervous System Agents, V2, P229, DOI 10.2174/1568015023358058
  • [2] Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group
    Bartolucci, Cecilia
    Stojan, Jure
    Yu, Qian-sheng
    Greig, Nigel H.
    Lamba, Doriano
    [J]. BIOCHEMICAL JOURNAL, 2012, 444 : 269 - 277
  • [3] Birks J., 2004, COCHRANE DB SYST REV, V4
  • [4] Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site
    Bourne, Y
    Taylor, P
    Radic, Z
    Marchot, P
    [J]. EMBO JOURNAL, 2003, 22 (01) : 1 - 12
  • [5] Cokugras AN., 2003, TURK J BIOCHEM, V28, P54, DOI DOI 10.1016/J.CBI.2005.10.013
  • [6] Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
    Colovic, Mirjana B.
    Krstic, Danijela Z.
    Lazarevic-Pasti, Tamara D.
    Bondzic, Aleksandra M.
    Vasic, Vesna M.
    [J]. CURRENT NEUROPHARMACOLOGY, 2013, 11 (03) : 315 - 335
  • [7] Corey-Bloom J., 1998, International Journal of Geriatric Psychopharmacology, V2, P55
  • [8] DUNNETT SB, 1993, PROG BRAIN RES, V98, P413
  • [9] Increased apoptotic cell death in sporadic and genetic Alzheimer's disease
    Eckert, A
    Marques, CA
    Keil, U
    Schüssel, K
    Müller, WE
    [J]. APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS, 2003, 1010 : 604 - 609
  • [10] Alzheimer's disease and anaesthesia: implications for the central cholinergic system
    Fodale, V.
    Quattrone, D.
    Trecroci, C.
    Caminiti, V.
    Santamaria, L. B.
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 2006, 97 (04) : 445 - 452